Disease-A-Month
Volume 54, Issue 7 , Pages 445-456 , July 2008

Complications of Cirrhosis

References 

  1. Kochanek KD, Murphy SL, Anderson RN, et al. Deaths: final data for 2002. Natl Vital Stat Rep. 2004;53:1–115
  2. Henderson NC, Iredale JP. Liver fibrosis: cellular mechanisms of progress and resolution. Clin Sci. 2007;112:265–280
  3. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112:463–472
  4. Nguyen TT, Lingappa VR. Liver Disease. In:  McPhee SJ,  Ganong WF editor. Pathophysiology of Disease: An Introduction to Clinical Medicine. 5th ed.. New York, NY: McGraw-Hill; 2006;p. 327–429
  5. Esrailian E, Saab S. Hematopoietic abnormalities and hemostasis. In:  Boyer TD,  Wright TL,  Manns MP editor. Hepatology: A Textbook of Liver Disease. 5th ed.. Canada: Saunders Elsevier; 2006;p. 489–499
  6. Levi MM, Vink R, de Jonge E. Management of bleeding disorders by prohemostatic therapy. Int J Hematol. 2002;76(suppl 2):139–144
  7. Carson JL, Willett LR. Toxicity of nonsteroidal anti-inflammatory drugs: an overview of the epidemiological evidence. Drugs. 1993;46(suppl 1):243–248
  8. Riley TR, Smith JP. Preventive care in chronic liver disease. J Gen Intern Med. 1999;14:699–704
  9. Angeli P, Wong F, Watson H, et al. CAPPS Investigators Hyponatremia in cirrhosis: results of a patient population survey. Hepatology. 2006;44:1535–1542
  10. Biggins SW, Kim WR, Terrault NA, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology. 2006;130:1652–1660
  11. Arroyo V, Terra C, Gines P. New treatments of hepatorenal syndrome. Semin Liv Dis. 2006;26:254–262
  12. Murphy N, Auzinger G, Bernel W, et al. The effect of hypertonic sodium chloride on intracranial pressure in patients with acute liver failure. Hepatology. 2004;39:464–470
  13. Schrier RW, Gross P, Gheorghiade M. Treatment for cirrhosis-related hyponatremia? (Vaptans and aquaresis). Hepatology. 2007;45:1080–1081
  14. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology. 1995;22:332–354
  15. McCormick PA, O'Keefe C. Improving prognosis following a first variceal hemorrhage over four decades. Gut. 2001;49:682–685
  16. Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology. 1981;80:800–809
  17. Triantos CK, Burroughs AK. Prevention of the development of varices and first portal hypertensive bleeding episode. Best Pract Res Clin Gastro. 2007;21:31–42
  18. Lowe RC, Grace ND. Primary prophylaxis of variceal hemorrhage. Clin Liver Dis. 2001;5:665–676
  19. Mathews RI, McGuire BM, Estrada CA. Outpatient management of cirrhosis: a narrative review. South Med J. 2006;99:600–606
  20. Poynard T, Cales P, Pasta L, et al. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices: an analysis of data and prognostic factors in 589 patients from four randomized clinical trials. N Engl J Med. 1991;324:1532–1538
  21. Schepke M, Kleber G, Numberg D, et al. Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology. 2004;40:65–72
  22. Thabut D, Bernard-Chabert B. Management of acute bleeding from portal hypertension. Best Pract Res Clin Gastro. 2007;21:19–29
  23. Henderson JM. Surgery versus transjugular intrahepatic portal systemic shunt in the treatment of severe variceal bleeding. Clin Liver Dis. 2006;10:599–612
  24. Somberg KA, Riegler JL, LaBerge JM, et al. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunts: incidence and risk factors. Am J Gastroenterol. 1995;90:549–555
  25. Saab S, Nieto JM, Lewis SK, et al. TIPS versus paracentesis for cirrhotic patients with refractory ascites. Cochrane Database Syst Rev. 2006;18(4):CD004889
  26. LaBerge JM, Somberg KA, Lake JR, et al. Two-year outcome following transjugular intrahepatic portosystemic shunt for variceal bleeding: results in 90 patients. Gastroenterology. 1995;108:1143–1151
  27. Martin PY, Gines P, Schrier RW. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med. 1998;339:553-41
  28. Sandhu BS, Sanyal AJ. Management of ascites in cirrhosis. Clin Liv Dis. 2005;9:715–732
  29. Fogel MR, Sawheney VK, Neal EA, et al. Diuresis in the ascetic patient: a randomized controlled trial of three regimens. J Clin Gastroenterol. 1981;3:73–80
  30. D'Amico G, Morabito A, Pagliaro L, et al. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci. 1986;31:468–475
  31. Laffi G, Gentilini P, Romanelli RG, et al. Is the use of albumin of value in the treatment of ascites in cirrhosis? (The case in favor). Dig Liver Dis. 2003;35:660–663
  32. Gentilini P, Casini-Raggi V, Di Fiore G, et al. Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. J Hepatol. 1999;30:639–645
  33. Sanyal AJ, Genning C, Reddy KR, et al. The North American study for the treatment of refractory ascites. Gastroenterology. 2003;124:634–641
  34. Rimola A, Garcia-Tsao G, Navasa M, et al. Diagnosis, treatment, and prophylaxis of spontaneous bacterial peritonitis: a consensus document (International Ascites Club). J Hepatol. 2000;32:142–153
  35. Tito L, Rimola A, Gines P, et al. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology. 1988;8:27–31
  36. Follo A, Llovet JM, Navasa M, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and progress. Hepatology. 1994;20:1495–1501
  37. Wright G, Jalan R. Management of hepatic encephalopathy in patients with cirrhosis. Best Pract Res Clin Gastro. 2007;21:95–110
  38. Cordoba J, Lopez-Hellin J, Planas M, et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol. 2004;41:38–43
  39. Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology. 1993;105:229–236
  40. Herve P, Le Pavec J, Sztrymf B, et al. Pulmonary vascular abnormalities in cirrhosis. Best Pract Res Clin Gastro. 2007;21:141–159
  41. Reichenberger F, Voswinckel R, Steveling E, et al. Sildenafil treatment for portopulmonary hypertension. Eur Respir J. 2006;28:563–567
  42. Chua R, Koegh A, Miyashita M. Novel use of sildenafil in the treatment of portopulmonary hypertension. J Heart Lung Transplant. 2005;24:498–500
  43. Saab S, Ly D, Nieto J, et al. Hepatocellular carcinoma screening in patients waiting for liver transplantation: a decision analytic mode. Liver Transpl. 2003;9:672–681
  44. Lu DS, Yu NC, Raman SS, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology. 2005;41:1130–1137
  45. Francoz C, Belghiti J, Durand F. Indications of liver transplantation in patients with complications of cirrhosis. Best Pract Res Clin Gastro. 2007;21:175–190
  46. Freeman RB, Wiesner RH, Harper A, et al. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl. 2002;8:851–858
  47. Kamath PS, Kim WR. The model for end-stage liver disease (MELD). Hepatology. 2007;45:797–805

PII: S0011-5029(08)00041-2

doi: 10.1016/j.disamonth.2008.03.006

Disease-A-Month
Volume 54, Issue 7 , Pages 445-456 , July 2008

Article Tools